Trials / Completed
CompletedNCT01015404
A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Kaken Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the safety in using Trafermin (recombinant human basic fibroblast growth factor) with periodontal surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trafermin | Administered to the bone defect during flap operation |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-03-01
- First posted
- 2009-11-18
- Last updated
- 2013-10-21
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01015404. Inclusion in this directory is not an endorsement.